Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2021-07-30 Regulatory Filings
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2021-07-30 English
6-K
Regulatory Filings
2021-07-30 English
6-K
Regulatory Filings
2021-07-30 English
QIAGEN reports full results for Q2 and H1 2021
Regulatory Filings
2021-07-30 English
Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase
Transaction in Own Shares Classification · 100% confidence The document explicitly announces the start of a 'Share Repurchase program' ('Aktienrückkaufprogramm') by QIAGEN N.V., detailing the timeline, maximum purchase price, and regulatory compliance (EU Regulation 596/2014). A share repurchase is a transaction where a company buys back its own shares. This directly corresponds to the definition for 'Transaction in Own Shares' (Code: POS). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it describes a specific corporate action related to capital management.
2021-07-20 German
QIAGEN announces preliminary Q2 2021 results and updates 2021 outlook/QIAGEN to conduct an additional up to USD 100 million share repurchase program
Earnings Release Classification · 100% confidence The document explicitly states it is an 'Ad hoc Announcement according to Art. 17 Market Abuse Regulation' and provides 'preliminary Q2 2021 results and updates 2021 outlook'. This content—the initial release of key financial figures (net sales, adjusted EPS) for a period, often before the full report—is the definition of an Earnings Release (ER). Although it updates the outlook, the primary function here is the preliminary earnings announcement. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), nor is it a transcript (CT) or a presentation (IP). Given the short length (under 5,000 characters) and the nature of announcing preliminary results, ER is the most appropriate classification. Q2 2021
2021-07-13 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.